Owners, management and financials
CVR: 44445832
Previous names: Selskabet af 21. november 2023 ApS
EUR -866,109
Gross profit
Net result: EUR -892,687
CLAUS OLESEN HOLDING ApS (50-66,65%), MR Jakobsen Holding ApS (15-19,99%)
1 more
CVR · view owners
Claus Elsborg Olesen
Board: Sten Verland (chair) and 2 members
CVR · view management
Active
Founded 21 November 2023
CVR · view overview
2 employees
CVR · 2026
Name registered: Sulis Therapeutics ApS
CVR · 27/06/2024
View the full event history
Sulis Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Selskabet af 21. november 2023 ApS. The management consists of Claus Elsborg Olesen. The board consists of Sten Verland (chair), Claus Elsborg Olesen and Martin Roelsgaard Jakobsen. The company is owned by CLAUS OLESEN HOLDING ApS, MR Jakobsen Holding ApS and Shinka Life Sciences AB. The company has 2 employees (2026). In 2025, the company reported a gross profit of EUR -866,109 and a net result of EUR -892,687 compared with EUR -202,314 the year before. Equity in the 2025 report amounted to EUR -938,524.
Selskabets formål er udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -866K EUR | -893K EUR | 1.5M EUR | -939K EUR | 1 | |
| 202401/01/2024 – 31/12/2024 | -167K EUR | -202K EUR | 533K EUR | -46K EUR | 1 |
Compared to 1.035 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of Sulis Therapeutics ApS is 44445832.
Sulis Therapeutics ApS is owned by CLAUS OLESEN HOLDING ApS, MR Jakobsen Holding ApS and Shinka Life Sciences AB.
The management of Sulis Therapeutics ApS consists of Claus Elsborg Olesen.
The board of Sulis Therapeutics ApS consists of Sten Verland, Claus Elsborg Olesen and Martin Roelsgaard Jakobsen, with Sten Verland as chair.
In 2025, Sulis Therapeutics ApS reported a gross profit of EUR -866,109.
Sulis Therapeutics ApS had 2 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Sulis Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -866,109, and the net result was DKK -892,687.
As of June 1, 2026, Claus Elsborg Olesen has joined the board of directors of Sulis Therapeutics ApS.
As of June 1, 2026, Sten Verland has joined the board of directors of Sulis Therapeutics ApS.
As of May 31, 2026, Claus Elsborg Olesen has left the board of directors of Sulis Therapeutics ApS.
As of August 5, 2025, Claus Elsborg Olesen has joined the board of directors of Sulis Therapeutics ApS.
As of August 5, 2025, Martin Roelsgaard Jakobsen has joined the board of directors of Sulis Therapeutics ApS.
Sulis Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -167,138, and the net result was DKK -202,314.
As of June 27, 2024, Sten Verland has left the board of directors of Sulis Therapeutics ApS.
As of June 27, 2024, Morten Døssing has left the board of directors of Sulis Therapeutics ApS.
As of June 27, 2024, Martin Roelsgaard Jakobsen has left the board of directors of Sulis Therapeutics ApS.
As of June 27, 2024, Christian Schetter has left the board of directors of Sulis Therapeutics ApS.
As of June 27, 2024, Regina Hodits has left the board of directors of Sulis Therapeutics ApS.
On June 27, 2024, the company changed its name from Selskabet af 21. november 2023 ApS to Sulis Therapeutics ApS.
As of May 23, 2024, CLAUS OLESEN HOLDING ApS is registered as an owner of Sulis Therapeutics ApS with an ownership share of 50%.
As of May 23, 2024, MR Jakobsen Holding ApS is registered as an owner of Sulis Therapeutics ApS with an ownership share of 15%.
As of May 23, 2024, is registered as an owner of Sulis Therapeutics ApS with an ownership share of 25%.
Sulis Therapeutics ApS has published its interim report for the period November 21, 2023 to December 31, 2023.
As of December 31, 2023, Natalie Rose Sacks has left the board of directors of Sulis Therapeutics ApS.
As of November 21, 2023, EY Godkendt Revisionspartnerselskab has been appointed auditor of Sulis Therapeutics ApS.
As of November 21, 2023, Sten Verland has joined the board of directors of Sulis Therapeutics ApS.
As of November 21, 2023, Morten Døssing has joined the board of directors of Sulis Therapeutics ApS.
As of November 21, 2023, Martin Roelsgaard Jakobsen has joined the board of directors of Sulis Therapeutics ApS.
As of November 21, 2023, Christian Schetter has joined the board of directors of Sulis Therapeutics ApS.
As of November 21, 2023, Natalie Rose Sacks has joined the board of directors of Sulis Therapeutics ApS.
As of November 21, 2023, Regina Hodits has joined the board of directors of Sulis Therapeutics ApS.
As of November 21, 2023, Claus Elsborg Olesen is registered as director of Sulis Therapeutics ApS.
Sulis Therapeutics ApS was founded on November 21, 2023.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at drive virksomhed med handel og produktion samt hermed beslægtet virksomhed.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Companies in the same industry and area
CVR 36465972
CVR 45436497
CVR 46059220
CVR 41978074
CVR 46543912
